163 related articles for article (PubMed ID: 34407041)
61. Treatment of splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
[TBL] [Abstract][Full Text] [Related]
62. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.
Olszewski AJ
Am J Hematol; 2012 Nov; 87(11):E119-22. PubMed ID: 22887176
[TBL] [Abstract][Full Text] [Related]
63. NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
Alderuccio JP; Lossos IS
Leuk Lymphoma; 2022 Feb; 63(2):279-290. PubMed ID: 34586000
[TBL] [Abstract][Full Text] [Related]
64. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):371-378. PubMed ID: 29222281
[TBL] [Abstract][Full Text] [Related]
65. An insidious presentation of splenic marginal zone lymphoma.
Burcheri S; Arcaini L; Della Porta M; Paulli M; Boveri E; Zibellini S; Rumi E; Algarotti A; Passamouti F; Lazzarino M
Clin Lymphoma Myeloma; 2007 May; 7(6):432-3. PubMed ID: 17621411
[TBL] [Abstract][Full Text] [Related]
66. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
67. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
[No Abstract] [Full Text] [Related]
68. Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?
Mollejo M; Algara P; Mateo MS; Sánchez-Beato M; Lloret E; Medina MT; Piris MA
Histopathology; 2002 Jan; 40(1):22-30. PubMed ID: 11903595
[TBL] [Abstract][Full Text] [Related]
69. Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma.
Munari E; Rinaldi M; Ambrosetti A; Bonifacio M; Bonalumi A; Chilosi M; Zamò A
Virchows Arch; 2012 Dec; 461(6):677-85. PubMed ID: 23064660
[TBL] [Abstract][Full Text] [Related]
70. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification.
Traverse-Glehen A; Baseggio L; Salles G; Felman P; Berger F
Curr Opin Oncol; 2011 Sep; 23(5):441-8. PubMed ID: 21760505
[TBL] [Abstract][Full Text] [Related]
71. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
[TBL] [Abstract][Full Text] [Related]
72. [Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow].
Sun Q; Zhang PH; Liu EB; Liu W; Li ZQ; Yang QY; Fang LH; Sun FJ; Chen HS; Qiu LG
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):234-8. PubMed ID: 23928529
[TBL] [Abstract][Full Text] [Related]
73. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
[TBL] [Abstract][Full Text] [Related]
74. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
[TBL] [Abstract][Full Text] [Related]
75. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.
Hoehn D; Miranda RN; Kanagal-Shamanna R; Lin P; Medeiros LJ
Hum Pathol; 2012 Nov; 43(11):1828-38. PubMed ID: 22520947
[TBL] [Abstract][Full Text] [Related]
76. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.
Fallah J; Olszewski AJ
Hematology; 2019 Dec; 24(1):378-386. PubMed ID: 30885066
[TBL] [Abstract][Full Text] [Related]
77. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
Byrd KP; Vontela NR; McCullar B; Martin MG
Anticancer Res; 2017 Dec; 37(12):6839-6843. PubMed ID: 29187463
[TBL] [Abstract][Full Text] [Related]
78. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
79. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.
Martínez N; Almaraz C; Vaqué JP; Varela I; Derdak S; Beltran S; Mollejo M; Campos-Martin Y; Agueda L; Rinaldi A; Kwee I; Gut M; Blanc J; Oscier D; Strefford JC; Martinez-Lopez J; Salar A; Sole F; Rodriguez-Peralto JL; Diez-Tascón C; García JF; Fraga M; Sebastián E; Alvés J; Menárguez J; González-Carreró J; Casado LF; Bayes M; Bertoni F; Gut I; Piris MA
Leukemia; 2014 Jun; 28(6):1334-40. PubMed ID: 24296945
[TBL] [Abstract][Full Text] [Related]
80. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features.
Mollejo M; Lloret E; Menárguez J; Piris MA; Isaacson PG
Am J Surg Pathol; 1997 Jul; 21(7):772-80. PubMed ID: 9236833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]